Multivariable models
| Variable . | OS HR (95% CI) . | EFS HR (95% CI) . | CR or CRi OR (95% CI) . | RFS if CR/CRi HR (95%CI) . |
|---|---|---|---|---|
| WHO AML (ref MDS-EB2) | 0.89 (0.74-1.07) | 0.89 (0.75-1.06) | 1.06 (0.99-1.13) | 0.66 (0.53-0.83) |
| P | .21 | .2 | .11 | <.001 |
| Age (per 10 y) | 1.3 (1.22-1.38) | 1.19 (1.13-1.26) | 0.98 (0.96-1) | 1.13 (1.05-1.2) |
| P | <.001 | <.001 | .02 | <.001 |
| PS 2-4 (ref PS 0-1) | 2 (1.68-2.37) | 1.68 (1.42-1.99) | 0.87 (0.82-0.93) | 1.21 (0.96-1.51) |
| P | <.001 | <.001 | <.001 | .11 |
| ELN 2017 intermediate risk (ref favorable risk) | 1.7 (1.34-2.15) | 1.72 (1.38-2.14) | 0.86 (0.8-0.93) | 2.15 (1.67-2.76) |
| P | <.001 | <.001 | <.001 | <.001 |
| ELN 2017 adverse risk (ref favorable risk) | 2.28 (1.8-2.88) | 2.29 (1.84-2.85) | 0.78 (0.73-0.84) | 3.07 (2.35-4) |
| P | <.001 | <.001 | <.001 | <.001 |
| Secondary (ref de novo) | 1.3 (1.1-1.55) P = 0.002 | 1.28 (1.08-1.5) P = 0.004 | 0.93 (0.87-0.99) P = 0.02 | 1.16 (0.93-1.43) P = 0.18 |
| P | .002 | .004 | .02 | .18 |
| Low-intensity induction (ref high intensity) | 1.3 (1.08-1.55) | 1.62 (1.36-1.93) | 0.7 (0.66-0.75) | 1.07 (0.82-1.38) |
| P | .004 | <.001 | <.001 | .63 |
| Allogeneic HCT (ref no allogeneic HCT) | 0.48 (0.39-0.6) | 0.39 (0.31-0.47) | Not applicable | 0.29 (0.23-0.36) |
| P | <.001 | <.001 | <.001 |
| Variable . | OS HR (95% CI) . | EFS HR (95% CI) . | CR or CRi OR (95% CI) . | RFS if CR/CRi HR (95%CI) . |
|---|---|---|---|---|
| WHO AML (ref MDS-EB2) | 0.89 (0.74-1.07) | 0.89 (0.75-1.06) | 1.06 (0.99-1.13) | 0.66 (0.53-0.83) |
| P | .21 | .2 | .11 | <.001 |
| Age (per 10 y) | 1.3 (1.22-1.38) | 1.19 (1.13-1.26) | 0.98 (0.96-1) | 1.13 (1.05-1.2) |
| P | <.001 | <.001 | .02 | <.001 |
| PS 2-4 (ref PS 0-1) | 2 (1.68-2.37) | 1.68 (1.42-1.99) | 0.87 (0.82-0.93) | 1.21 (0.96-1.51) |
| P | <.001 | <.001 | <.001 | .11 |
| ELN 2017 intermediate risk (ref favorable risk) | 1.7 (1.34-2.15) | 1.72 (1.38-2.14) | 0.86 (0.8-0.93) | 2.15 (1.67-2.76) |
| P | <.001 | <.001 | <.001 | <.001 |
| ELN 2017 adverse risk (ref favorable risk) | 2.28 (1.8-2.88) | 2.29 (1.84-2.85) | 0.78 (0.73-0.84) | 3.07 (2.35-4) |
| P | <.001 | <.001 | <.001 | <.001 |
| Secondary (ref de novo) | 1.3 (1.1-1.55) P = 0.002 | 1.28 (1.08-1.5) P = 0.004 | 0.93 (0.87-0.99) P = 0.02 | 1.16 (0.93-1.43) P = 0.18 |
| P | .002 | .004 | .02 | .18 |
| Low-intensity induction (ref high intensity) | 1.3 (1.08-1.55) | 1.62 (1.36-1.93) | 0.7 (0.66-0.75) | 1.07 (0.82-1.38) |
| P | .004 | <.001 | <.001 | .63 |
| Allogeneic HCT (ref no allogeneic HCT) | 0.48 (0.39-0.6) | 0.39 (0.31-0.47) | Not applicable | 0.29 (0.23-0.36) |
| P | <.001 | <.001 | <.001 |
Time-dependent Cox regression for OS, EFS, and RFS; logistic regression for CR/CRi and CRMRD−.
HR, hazard ratio; OR, odds ratio.